One Wharton's-jelly MSC platform — live cells, cell-free secretome, and purified exosomes — produced inside an FDA-registered U.S. cGMP cell & gene therapy quality system, alongside a growing family of partner products.
Made Scientific is a U.S.-based cGMP cell & gene therapy CDMO owned by GC Cell, part of the GC (Green Cross) group of South Korea — a multi-decade healthcare organization spanning cell & gene therapy, biopharmaceuticals, aesthetics, and consumer health.
The mesenchymal stromal cell (MSC) and its secretome — the mixture of growth factors and extracellular vesicles (exosomes) it releases — carry the angiogenic and matrix-remodeling signals behind regenerative and aesthetic outcomes. Made Scientific manufactures the full range under one cGMP quality system, on a flexible model spanning Research-Use-Only through full GMP human-use release.
All Made products originate from allogeneic human umbilical-cord Wharton's-jelly MSCs — a neonatal, developmentally young source associated in the literature with higher extracellular-vesicle yield and angiogenic potency than adult bone-marrow sources, with no age-related donor senescence, and an off-the-shelf allogeneic manufacturing model.
Material is supplied Research-Use-Only (RUO) through to full GMP human-use release. No disease-treatment claims are made; clinical material referenced here is presented as literature evidence and intended-use only. Human use requires appropriate regulatory authorization.
Grouped by manufacturing platform and origin. 2D = planar / adherent culture (the current specified process); 3D = suspension / bioreactor culture (the higher-scale development track). Secretome and exosome ship today as liquid cryopreserved, with lyophilized derivatives on the 2027 roadmap.
Allogeneic Wharton's-jelly umbilical-cord MSC drug product, expanded under a full cGMP quality system and released against defined identity (CD73/CD90/CD105), viability, and safety criteria. Custom release testing available for higher-dose and clinical programs.
The core cell-free product: conditioned, clarified, sterile-filtered MSC secretome — growth factors (e.g., VEGF, HGF, bFGF) plus extracellular vesicles, no cells present — formulated and filled ready to use across regenerative and aesthetic protocols.
Purified extracellular-vesicle (exosome) product isolated from MSC-conditioned media and characterized by particle size, count, and vesicle-integrity markers (NTA). Configured to program-specific formats; Wharton's-jelly and bone-marrow-derived options.
The higher-scale manufacturing track for the WJ-MSC drug product — moving from planar culture into closed automated suspension bioreactors to support larger, more consistent allogeneic batches for commercial-scale supply.
Secretome harvested from MSCs cultured at bioreactor scale — the same conditioned-media product as the 2D secretome, produced through a higher-throughput suspension platform to meet larger distributor and market demand.
Purified MSC exosomes produced from bioreactor-scale suspension culture, targeting the higher particle yields needed for broader regenerative and aesthetic supply, with the same characterization panel as the 2D product.
A freeze-dried presentation of the MSC secretome for extended shelf life, simpler non-cold-chain transport, and point-of-use reconstitution — offered from 2027 in addition to the current liquid cryopreserved format. A long-term (36-month) stability program is an active goal.
A freeze-dried presentation of the purified MSC exosome product for extended shelf life and easier distribution — offered from 2027 alongside the current liquid cryopreserved format, enabling non-cold-chain logistics and reconstitute-at-use workflows.
A partner-derived bone-marrow MSC exosome produced from a proprietary Master Cell Bank using 2D and 3D bioreactor processes — spanning a naive (unloaded) exosome supply track and an siRNA-loaded clinical nanodrug platform, characterized for batch-to-batch consistency by independent proteomic protein-fingerprint analysis.
A human oral-mucosal (neural-crest) stem cell product from Made's publicly announced partner Cytora, expanded via 2D adherent culture — a complementary MSC source on the roadmap for distributor supply, with intended-use context in wound care (diabetic foot ulcers) and broader orthopedic / pain applications.
A future aesthetic neurotoxin line from the GC (Green Cross) family, envisioned as a roadmap extension distributed through Made's regenerative channel — pairing an injectable aesthetic franchise with Made's cell-derived products. Planned, not yet available.
A future consumer-health line — nutraceuticals and OTC wellness products — envisioned within the GC (Green Cross) family and positioned as a roadmap complement to Made's regenerative and longevity portfolio. Planned, not yet available.
An evidence-based review of MSC-derived secretome and exosomes for hair restoration, skin rejuvenation, and regenerative wellness — biology, mechanisms, the clinical evidence landscape, safety, and regulatory framing. Grounded in the published literature; no disease-treatment claims.
Made Scientific manufactures its regenerative line inside an FDA-registered cell & gene therapy CDMO quality system — the same GMP infrastructure used for clinical cell-therapy manufacture. Operations align to FDA 21 CFR 210/211 and 1271 and ICH Q7, Q9, and Q10, with an independent Quality Unit holding final batch-disposition authority (ALCOA+ data integrity, formal change control, CAPA, supplier qualification).
Allogeneic human umbilical-cord Wharton's-jelly MSC (hUC-WJ-MSC), procured under 21 CFR 1271 and AATB standards (IRB oversight, informed consent, donor eligibility and infectious-disease testing). The neonatal source is associated in the literature with higher EV yield and angiogenic potency and no age-related senescence.
2D = planar / adherent culture, the current documented and specified process for every product. 3D = suspension / bioreactor culture, the higher-scale path enabling larger, more consistent batches — presented as a development / scale-up track.
Today, secretome and exosome ship liquid cryopreserved on an LN₂ vapor-phase cold chain with full chain-of-custody. From 2027, lyophilized derivatives add extended shelf life and non-cold-chain transport, offered in addition to the liquid format.
Each lot is characterized through industry-standard testing — sterility, endotoxin (LAL), mycoplasma, total protein, particle characterization (NTA), and functional potency. Live MSC drug product adds identity by flow cytometry, post-thaw viability, plastic adherence, and trilineage differentiation.
Each lot is released against an agreed certificate of analysis covering identity, viability, sterility, endotoxin, mycoplasma, and functional potency.
An independent Quality Unit holds final batch-disposition authority, with ALCOA+ data integrity, formal change control, CAPA, and supplier qualification.
Controlled-rate freeze with end-to-end cold-chain logistics (LN₂ vapor phase) and full chain-of-custody, suitable for reliable domestic and international shipment.
Flexible supply model: material is available as RUO through GMP — from Research-Use-Only through to full GMP human-use release. Specific numeric acceptance thresholds are internal quality criteria and are provided under separate cover with the product specification.
Made Scientific's Longevity Medicine Research Series is a literature-grounded synthesis of the biology underpinning our regenerative portfolio, organized around three converging pillars: mesenchymal stromal cells, their cell-free secretome and extracellular vesicles, and senolytic and senotherapeutic approaches to cellular aging. Each pillar traces what the peer-reviewed evidence does and does not yet establish, spanning research-use-grade through GMP manufacturing. It is intended as scientific and educational context on the mechanisms studied in aging biology, not as treatment, efficacy, or anti-aging claims for any Made product.
MSCs act as "medicinal signaling cells" that are largely cleared within days yet direct endogenous repair through paracrine signaling — a mechanism the aging literature studies for its potential to engage several hallmarks of aging at once, including the inflammatory "inflammaging" axis (Caplan 2017, Stem Cells Transl Med).
Mesenchymal stromal cells (MSCs) are multipotent adult cells that act largely as "medicinal signaling cells": after administration most are cleared within a few days, yet they direct tissue repair through paracrine secretion of growth factors, extracellular vesicles, and immunomodulatory signals rather than long-term engraftment. Made Scientific works with two allogeneic, off-the-shelf source tissues — adult bone-marrow MSC (BM-MSC), the most clinically studied class, and neonatal Wharton's-jelly umbilical-cord MSC (WJ-MSC), which offers faster expansion, a younger epigenetic profile, and low immunogenicity for repeat dosing. The platform spans research-use-grade through GMP manufacturing.
Biodistribution studies show systemically infused MSCs are largely cleared within 24–72 hours, yet measurable effects can persist for weeks — supporting a "hit-and-run" model in which MSCs act as environment sensors that secrete VEGF, HGF, IGF-1, extracellular vesicles, and immunomodulatory mediators to orchestrate endogenous repair (Caplan 2017, Stem Cells Transl Med; Prockop & Oh 2012, Mol Ther).
MSCs respond to inflammatory cues (IFN-γ, TNF-α) by upregulating IDO, PGE2, TSG-6 and IL-10 and by polarizing macrophages toward an anti-inflammatory M2 phenotype. Placebo-controlled early-phase frailty studies reported reductions in circulating inflammatory markers (including TNF-α) after MSC infusion — the same inflammatory axis central to "inflammaging" (Tompkins et al. 2017; Golpanian et al. 2017, J Gerontol A Biol Sci Med Sci).
In aging-biology models, MSCs are studied for modulating the senescence-associated secretory phenotype (SASP) and for transferring functional mitochondria to stressed cells via tunneling nanotubes and extracellular vesicles, restoring ATP production and reducing oxidative stress (Liu et al. 2020, Front Cell Dev Biol). These are proposed mechanisms under active investigation rather than established clinical outcomes.
Randomized early-phase trials in frail older adults reported improvements in six-minute walk distance and physical-performance measures versus placebo, alongside reduced inflammatory markers — among the few controlled functional endpoints in longevity research (Tompkins et al. 2017; Golpanian et al. 2017, J Gerontol A Biol Sci Med Sci). Later-phase frailty trials have since been undertaken, but large confirmatory, peer-reviewed efficacy data remain limited.
MSC-secreted angiogenic factors (VEGF, HGF) drive neovascularization and re-epithelialization; published Phase I/II work in diabetic and chronic wounds describes accelerated closure and angiogenesis. Here the mechanism is better characterized than the clinical evidence base, which is graded emerging.
Wharton's-jelly MSCs show longer telomeres, a younger epigenetic profile, roughly 30–50 population doublings before senescence, and low HLA class I with negligible class II expression — properties suited to repeat allogeneic dosing without HLA matching, which longevity research protocols favor over donor-age-limited bone-marrow sources (Hass et al. 2011, Cell Commun Signal; Mushahary et al. 2018, Cytometry Part A).
Evidence strength varies sharply by indication, and the published literature (not Made products) is the basis for every statement here. Strongest: pediatric steroid-refractory acute graft-versus-host disease, supported by multiple Phase III trials and three regulatory approvals (US FDA, Japan PMDA, Health Canada); and knee osteoarthritis / cartilage defects, with a structural-endpoint Phase III basis behind Korea's MFDS approval. Moderate: Crohn's perianal fistula (EMA-approved 2018, later withdrawn from the EU market in 2024), spinal cord injury, acute myocardial infarction, critical limb ischemia, and ARDS (where meta-analyses have suggested a possible mortality benefit, though no product is approved to date). Emerging / early: diabetic wound healing, ALS, chronic pain, liver cirrhosis, and frailty / longevity, where early-phase functional signals exist but large confirmatory RCTs and human lifespan data are lacking. Across the field, donor-to-donor potency variability and the absence of standardized potency assays remain the central scientific challenge.
A growing body of evidence indicates much of the regenerative activity attributed to MSCs is carried by their cell-free secretome and vesicle cargo — positioning defined, particle-quantified, MISEV2023-characterized EV preparations as a research platform for tissue-repair and healthspan investigation (Welsh et al. 2024, J Extracell Vesicles).
MSC secretome and extracellular vesicles (EVs, including exosomes) are the cell-free fraction of what mesenchymal stromal cells release — a complex payload of growth factors, cytokines, signalling lipids, and vesicle-packaged microRNA and protein cargo. A growing body of published evidence indicates that much of the regenerative and immunomodulatory activity historically attributed to MSCs is carried by this paracrine secretome rather than by cells engrafting. As acellular preparations, secretome and purified exosomes can be quantified by particle count and protein mass, filtered, concentrated, and formulated — including as lyophilised, ambient-stable material — for research and manufacturing use across RUO-through-GMP contexts.
Conditioned-medium transfer, EV-depletion, and miRNA-knockout studies in the published literature indicate MSC therapeutic signals are largely mediated by secreted factors and EV cargo — VEGF, HGF, IGF-1, TGF-β, IL-10, and microRNAs such as miR-21, miR-146a, and miR-125b — rather than by cell engraftment or differentiation.
Small EVs / exosomes (~30–150 nm) arise from the endosomal pathway and carry tetraspanins (CD9, CD63, CD81), ESCRT proteins (Alix, TSG101), bioactive lipids, and selectively packaged short RNA and protein cargo that modulate recipient-cell gene expression and signalling upon uptake (Witwer et al., 2019, J Extracell Vesicles).
MSC-EVs are described in the aging literature as SASP-modulating biologics — transferring anti-inflammatory microRNAs (e.g. miR-146a targeting NF-κB), antioxidant peroxiredoxins, and mitochondrial components that mitigate oxidative-stress-driven cellular senescence in preclinical models (Ha et al., 2020, Cells).
Published observational dermatology cohorts report improvements in skin elasticity, wrinkle depth, hydration, and barrier function following topical or microneedling-assisted MSC-EV use, and androgenetic alopecia is among the more actively studied aesthetic indications. This evidence is early-stage and largely uncontrolled rather than confirmatory.
The field's MISEV2023 reporting framework (Welsh et al., 2024, J Extracell Vesicles) defines EV identity through orthogonal particle counting (NTA/TRPS), size distribution, positive markers (tetraspanins, Alix/TSG101), negative markers (calnexin, GM130), electron microscopy, and a functional potency assay — enabling defined, dose-by-particle-count product definition.
Bone-marrow (BM-MSC) and Wharton's-jelly (WJ-MSC) starting materials yield EVs with different cargo and potency profiles, and whole secretome, crude EV, and purified exosome formats trade off yield, purity, and manufacturability — considerations that inform product design for a given research application.
Framed on GRADE-style criteria from the published literature, the strongest MSC-EV clinical signal sits in inflammatory / immune contexts — COVID-19 ARDS and pneumonia carry the most trial activity and the earliest randomized data (moderate). Chronic wounds and skin regeneration are low-to-moderate maturity (mostly Phase I/II). Dermatology / aesthetics (photoaging, hyperpigmentation, alopecia) and osteoarthritis are early-stage (low). Longevity and healthy-aging applications remain preclinical / observational, with no dedicated registered trials — skin-aging biomarkers serve as proxy endpoints. Most indications therefore rest on early-phase or observational evidence rather than confirmatory RCTs.
Because senescent-cell accumulation is a hallmark shared across age-related decline, reducing that burden — through active immune clearance or by antagonizing its inflammatory secretome — is one of the more direct levers studied on healthspan, building on the genetic proof-of-concept that clearing senescent cells extends healthspan in mice (Baker et al. 2011, Nature).
Senolytics and senotherapeutics aim to reduce the burden of senescent cells — damaged cells that permanently stop dividing yet persist in tissue and secrete a pro-inflammatory mix of signals that drives aging. Made's research in this area spans three complementary approaches to the same underlying biology: NK-cell senotherapy (active immune clearance of senescent cells), young-fibroblast secretome, and iPSC-derived secretome (paracrine tissue rejuvenation and SASP suppression). The unifying thesis in the field is that lowering senescent-cell load, or antagonizing the inflammatory secretome it produces, may help restore tissue homeostasis in the context of aging and age-related disease.
Cellular senescence is a largely irreversible growth-arrest state triggered by telomere attrition, DNA damage, or oncogenic and metabolic stress. Senescent cells accumulate in aged tissue and resist apoptosis. Genetic proof-of-concept work showed that clearing p16-positive senescent cells delays age-related pathology and extends healthspan in mice (Baker et al., 2011, Nature; van Deursen lab).
Senescent cells secrete a complex senescence-associated secretory phenotype (SASP) of over 100 factors — inflammatory cytokines (IL-6, IL-8, TNF-α), chemokines, matrix metalloproteinases and growth factors — that can propagate senescence to neighboring cells and fuel chronic low-grade inflammation (inflammaging), which correlates with frailty and reduced healthspan (Coppé et al., 2008, PLoS Biol; Franceschi et al., 2018, Nat Rev Endocrinol).
Young organisms clear senescent cells efficiently, in part via natural killer (NK) cells that recognize stress ligands (MICA/MICB, ULBP) through NKG2D and DNAM-1. With age, NK surveillance declines, permitting senescent-cell accumulation — a self-reinforcing cycle in which the resulting SASP further suppresses immune function (Sagiv et al., 2016; Liu et al., 2023, Signal Transduct Target Ther).
Senolytics selectively induce apoptosis in senescent cells (e.g., dasatinib + quercetin, fisetin, navitoclax), while senomorphics suppress the SASP without killing the cells (e.g., rapamycin, metformin, JAK inhibitors). In the published literature the two approaches are increasingly viewed as complementary rather than competing.
Beyond passive apoptosis induction, biological senotherapeutics combine active immune clearance (NK cells) with paracrine rejuvenation: in the published fibroblast- and iPSC-secretome literature, young-fibroblast and iPSC-derived secretomes deliver growth factors and anti-inflammatory cargo (including exosomal miRNAs) that can antagonize the SASP and help remodel aged-tissue microenvironments.
Because lifespan requires decades to observe, healthspan is tracked over months using functional measures (grip strength, gait speed, frailty index), circulating SASP and senescence biomarkers, and second-generation epigenetic aging clocks (PhenoAge, GrimAge, DunedinPACE) that estimate biological age and mortality risk.
Evidence strength is uneven by approach and should be read carefully. Strongest is preclinical: NK-mediated senescent-cell clearance and its role in limiting fibrosis is well characterized across animal models. Small-molecule senolytics (dasatinib + quercetin, fisetin) have reached early-phase human trials in indications such as idiopathic pulmonary fibrosis, diabetic kidney disease, and Alzheimer's, with proof-of-mechanism reductions in senescence markers reported. Cell- and secretome-based senolytic use for systemic aging remains at the early-clinical and observational stage — cohorts to date are small, largely unblinded, and confounded by concurrent interventions, and no Phase III longevity trial has completed enrollment as of 2026. Healthspan and biological-age-clock signals in this space are therefore best framed as emerging rather than established.
These summaries distill a much larger body of peer-reviewed evidence, including where it remains early-stage or preclinical. Full pillar reports — with complete citations, evidence-grading, and the regulatory landscape (from RYONCIL's 2024 US FDA approval to the roughly 700 registered MSC trials) — are available to partners on request. All content is presented as scientific and educational context, not as treatment, efficacy, or anti-aging claims for any Made product.
Made Scientific supports a curated network of regenerative-medicine distributors through one master commercial framework — held constant across every partner, with deal-specific economics (territory, pricing, volume, branding) living in accompanying Schedules so new distributors can be appointed quickly and consistently. Products are supplied Research-Use-Only, manufactured under full U.S. cGMP with anti-diversion controls.
The complete Distributor Agreement — master terms plus Schedules A–I and Exhibits — is provided to qualified partners under separate cover and NDA. Talk to us to begin the appointment process.
Made backs its regenerative supply with a purpose-built software platform — a partner-enablement engine and a live longevity & regenerative-medicine intelligence radar — so distributors and partners get more than product. All three run on Made infrastructure, share one regenerative data layer, and sit alongside this portfolio on one domain family.
A live signal tracker for the longevity and regenerative-medicine field — news, regulation, and science lanes continuously ingested from RSS, PubMed, openFDA, the Federal Register, ClinicalTrials.gov, NIH RePORTER, SEC EDGAR and more, then triaged and summarized. Read-only intelligence for Made and its partners.
Open RadarA ready-to-brand console a distribution partner runs under its own identity: Education and a Resource Center, account segmentation and qualification, cold-calling and orders, plus a curated regen news stream — the turnkey commercial layer that lets a partner sell the regenerative line.
Open Partner ConsoleMade's own Tier-A outbound engine for distributors, large clinics, and brand partners — account segmentation, a regenerative fit score, positioning, and campaign orchestration on the shared regen data layer. Internal Made tooling, shown here for completeness.
Open ConsoleOne consolidated stack. The portfolio site, the two consoles, and the Radar all run on the same Made VPS behind the same reverse proxy, sharing one regenerative data layer — moving to a single *.made.bio domain family. No customer, pricing, or account data is exposed on this page; each tool is separately access-controlled.
Joe Sinclair
VP, Head of Commercial
joseph.sinclair@madescientific.comProduct & program inquiries — MSC drug product, secretome, exosome, and custom development, on an RUO-through-GMP supply model.
Distributor partnerships — appointment under the standardized distributor framework; the full agreement is available under NDA.
